Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

By Cory Renauer – Jun 10, 2020 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The partners will develop and hopefully commercialize up to seven new cancer drugs.

The pace of development for a handful of next-generation cancer therapies is about to get a huge boost. AbbVie (ABBV -5.96%) and Genmab (GMAB 0.63%) signed a collaboration deal on Wednesday involving three clinical-stage cancer drug candidates, plus up to four additional candidates down the road.

AbbVie and Genmab will jointly develop and commercialize three bispecific antibodies that can target surface proteins found on cancer cells with one side while the other side attracts tumor-hungry immune cells. The partners also agreed to apply each other's proprietary technology to four additional cancer drug candidates that they might find lingering in their libraries.

Pile of cash and prescription drugs.

Image source: Getty Images.

AbbVie will pay Genmab $750 million up front and up to $1.15 billion in milestone payments for the three candidates in development now, plus up to $2 billion more if four additional new cancer therapies emerge successfully from the partnership. They will share responsibilities for the development and commercialization of all candidates involved with the exception of the antibody furthest along in the development process, epcoritamab. If it's eventually approved, Genmab's eligible to receive a royalty percentage between 22% and 26% on sales of the CD-20 targeted antibody outside of the U.S. or Japan.

AbbVie isn't the only big pharmaceutical company investing heavily in bispecific antibody development. Late last year, Roche posted results that showed 54% of patients treated with its CD-20 targeting bispecific antibody, mosunetuzumab, responded to treatment, and 43% achieved complete remission. In a phase 1 study, an exciting 13 out of 15 lymphoma patients responded to treatment with monthly injections of epcoritamab.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$134.21 (-5.96%) $-8.51
Genmab A/S Stock Quote
Genmab A/S
$32.13 (0.63%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.